Therapeutic efficacy of peramivir against H5N1 highly pathogenic avian influenza viruses harboring the neuraminidase H275Y mutation

Antiviral Research

Volumn 139, Issue , 2017, Pages 41-48

  Kobayashi, Masanori ^a   Kodama, Makoto ^a   Noshi, Takeshi ^a   Yoshida, Ryu ^a   Kanazu, Takushi ^a   Nomura, Naoki ^b,c   Soda, Kosuke ^b,d   Isoda, Norikazu ^b,c   Okamatsu, Masatoshi ^b   Sakoda, Yoshihiro ^b,c   Yamano, Yoshinori ^a   Sato, Akihiko ^a,c   Kida, Hiroshi ^c  

^a SHIONOGI AND CO LTD   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d TOTTORI UNIVERSITY   (Japan)

Author keywords

H5N1; HPAI; Influenza; Mouse model; NAI; Peramivir

Indexed keywords

NEURAMINIDASE H275Y; OSELTAMIVIR; PERAMIVIR; UNCLASSIFIED DRUG; VIRUS SIALIDASE; ZANAMIVIR; ANTIVIRUS AGENT; CYCLOPENTANE DERIVATIVE; CYTOKINE; GUANIDINE DERIVATIVE; SIALIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; AVIAN INFLUENZA (H5N1); CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; ENZYME ASSAY; ENZYME INHIBITION; HIGHLY PATHOGENIC AVIAN INFLUENZA VIRUS; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA A VIRUS (H5N1); INFLUENZA A VIRUS (H7N1); INFLUENZA A VIRUS (H7N7); LETHALITY; LOW DRUG DOSE; MOUSE; MULTIPLE DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; THERAPY EFFECT; VIRUS MUTATION; VIRUS REPLICATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; IMMUNOLOGY; INFLUENZA; LUNG; MUTATION; ORTHOMYXOVIRUS INFECTION; PATHOGENICITY; VIROLOGY; VIRUS LOAD;

ANIMALS; ANTIVIRAL AGENTS; CYCLOPENTANES; CYTOKINES; DISEASE MODELS, ANIMAL; GUANIDINES; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA A VIRUS, H7N1 SUBTYPE; INFLUENZA A VIRUS, H7N7 SUBTYPE; INFLUENZA, HUMAN; LUNG; MICE; MUTATION; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; VIRAL LOAD; VIRUS REPLICATION;

EID: 85007586373     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2016.12.011     Document Type: Article

References (41)

1. Abed, Y., Simon, P., Boivin, G., Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H275Y neuraminidase mutation. Antimicrob. Agents Chemother. 54 (2010), 2819–2822.
2. Aymard-Henry, M., Coleman, M.T., Dowdle, W.R., Laver, W.G., Schild, G.C., Webster, R.G., Influenzavirus neuraminidase and neuraminidase-inhibition test procedures. Bull. World Health Organ 48 (1973), 199–202.
3. Baek, Y.H., Song, M.S., Lee, E.Y., Kim, Y.I., Kim, E.H., Park, S.J., Park, K.J., Kwon, H.I., Pascua, P.N., Lim, G.J., Kim, S., Yoon, S.W., Kim, M.H., Webby, R.J., Choi, Y.K., Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors. J. Virol. 89 (2015), 287–299.
4. Boltz, D.A., Ilyushina, N.A., Arnold, C.S., Babu, Y.S., Webster, R.G., Govorkova, E.A., Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice. Antivir. Res. 80 (2008), 150–157.
5. Capua, I., Mutinelli, F., Pozza, M.D., Donatelli, I., Puzelli, S., Cancellotti, F.M., The 1999-2000 avian influenza (H7N1) epidemic in Italy: veterinary and human health implications. Acta Trop. 83 (2002), 7–11.
6. Centers for Disease Control and Prevention (CDC), Highly Pathogenic Asian Avian Influenza a (H5N1) in People. 2015 http://www.cdc.gov/flu/avianflu/h5n1-people.htm (Accessed 1 September 2016.
7. Chan, M.C., Cheung, C.Y., Chui, W.H., Tsao, S.W., Nicholls, J.M., Chan, Y.O., Chan, R.W., Long, H.T., Poon, L.L., Guan, Y., Peiris, J.S., Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir. Res., 6, 2005, 135.
8. Cheung, C.Y., Poon, L.L., Lau, A.S., Luk, W., Lau, Y.L., Shortridge, K.F., Gordon, S., Guan, Y., Peiris, J.S., Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease?. Lancet 360 (2002), 1831–1837.
9. Collins, P.J., Haire, L.F., Lin, Y.P., Liu, J., Russell, R.J., Walker, P.A., Skehel, J.J., Martin, S.R., Hay, A.J., Gamblin, S.J., Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453 (2008), 1258–1261.
10. Dapat, C., Kondo, H., Dapat, I.C., Baranovich, T., Suzuki, Y., Shobugawa, Y., Saito, K., Saito, R., Suzuki, H., Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan. Antivir. Res. 99 (2013), 261–269.
11. de Jong, M.D., Simmons, C.P., Thanh, T.T., Hien, V.M., Smith, G.J., Chau, T.N., Hoang, D.M., Chau, N.V., Khanh, T.H., Dong, V.C., Qui, P.T., Cam, B.V., Ha do, Q., Guan, Y., Peiris, J.S., Chinh, N.T., Hien, T.T., Farrar, J., Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 12 (2006), 1203–1207.
12. de Jong, M.D., Tran, T.T., Truong, H.K., Vo, M.H., Smith, G.J., Nguyen, V.C., Bach, V.C., Phan, T.Q., Do, Q.H., Guan, Y., Peiris, J.S., Tran, T.H., Farrar, J., Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353 (2005), 2667–2672.
13. Gao, H.N., Lu, H.Z., Cao, B., Du, B., Shang, H., Gan, J.H., Lu, S.H., Yang, Y.D., Fang, Q., Shen, Y.Z., Xi, X.M., Gu, Q., Zhou, X.M., Qu, H.P., Yan, Z., Li, F.M., Zhao, W., Gao, Z.C., Wang, G.F., Ruan, L.X., Wang, W.H., Ye, J., Cao, H.F., Li, X.W., Zhang, W.H., Fang, X.C., He, J., Liang, W.F., Xie, J., Zeng, M., Wu, X.Z., Li, J., Xia, Q., Jin, Z.C., Chen, Q., Tang, C., Zhang, Z.Y., Hou, B.M., Feng, Z.X., Sheng, J.F., Zhong, N.S., Li, L.J., Clinical findings in 111 cases of influenza A (H7N9) virus infection. N. Engl. J. Med. 368 (2013), 2277–2285.
14. Gao, R., Cao, B., Hu, Y., Feng, Z., Wang, D., Hu, W., Chen, J., Jie, Z., Qiu, H., Xu, K., Xu, X., Lu, H., Zhu, W., Gao, Z., Xiang, N., Shen, Y., He, Z., Gu, Y., Zhang, Z., Yang, Y., Zhao, X., Zhou, L., Li, X., Zou, S., Zhang, Y., Li, X., Yang, L., Guo, J., Dong, J., Li, Q., Dong, L., Zhu, Y., Bai, T., Wang, S., Hao, P., Yang, W., Zhang, Y., Han, J., Yu, H., Li, D., Gao, G.F., Wu, G., Wang, Y., Yuan, Z., Shu, Y., Human infection with a novel avian-origin influenza a (H7N9) virus. N. Engl. J. Med. 368 (2013), 1888–1897.
15. Govorkova, E.A., Baranovich, T., Seiler, P., Armstrong, J., Burnham, A., Guan, Y., Peiris, M., Webby, R.J., Webster, R.G., Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring. Antivir. Res. 98 (2013), 297–304.
16. Govorkova, E.A., Leneva, I.A., Goloubeva, O.G., Bush, K., Webster, R.G., Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob. Agents Chemother. 45 (2001), 2723–2732.
17. Hernandez, J.E., Adiga, R., Armstrong, R., Bazan, J., Bonilla, H., Bradley, J., Dretler, R., Ison, M.G., Mangino, J.E., Maroushek, S., Shetty, A.K., Wald, A., Ziebold, C., Elder, J., Hollister, A.S., Sheridan, W., eIND Peramivir Investigators, Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States. Clin. Infect. Dis. 52 (2011), 695–706.
18. Hoffmann, E., Neumann, G., Hobom, G., Webster, R.G., Kawaoka, Y., “Ambisense” approach for the generation of influenza A virus: vRNA and mRNA synthesis from one template. Virology 267 (2000), 310–317.
19. Hurt, A.C., Holien, J.K., Barr, I.G., In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob. Agents Chemother. 53 (2009), 4433–4440.
20. Kitano, M., Itoh, Y., Ishigaki, H., Nakayama, M., Ishida, H., Pham, V.L., Arikata, M., Shichinohe, S., Tsuchiya, H., Kitagawa, N., Kobayashi, M., Yoshida, R., Sato, A., Le, Q.M., Kawaoka, Y., Ogasawara, K., Efficacy of repeated intravenous administration of peramivir against highly pathogenic avian influenza A (H5N1) virus in cynomolgus macaques. Antimicrob. Agents Chemother. 58 (2014), 4795–4803.
21. Kodama, M., Yoshida, R., Hasegawa, T., Izawa, M., Kitano, M., Baba, K., Noshi, T., Seki, T., Okazaki, K., Tsuji, M., Kanazu, T., Kamimori, H., Homma, T., Kobayashi, M., Sakoda, Y., Kida, H., Sato, A., Yamano, Y., The relationship between in vivo antiviral activity and pharmacokinetic parameters of peramivir in influenza virus infection model in mice. Antivir. Res. 109 (2014), 110–115.
22. Kohno, S., Kida, H., Mizuguchi, M., Hirotsu, N., Ishida, T., Kadota, J., Shimada, J., S-021812 Clinical Study Group. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrob. Agents Chemother. 55 (2011), 2803–2812.
23. Kohno, S., Kida, H., Mizuguchi, M., Shimada, J., S-021812 Clinical Study Group. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob. Agents Chemother. 54 (2010), 4568–4574.
24. Koopmans, M., Wilbrink, B., Conyn, M., Natrop, G., van der Nat, H., Vennema, H., Meijer, A., van Steenbergen, J., Fouchier, R., Osterhaus, A., Bosman, A., Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in The Netherlands. Lancet 363 (2004), 587–593.
25. Ku, A.S., Chan, L.T., The first case of H5N1 avian influenza infection in a human with complications of adult respiratory distress syndrome and Reye's syndrome. J. Paediatr. Child. Health 35 (1999), 207–209.
26. Lai, S., Qin, Y., Cowling, B.J., Ren, X., Wardrop, N.A., Gilbert, M., Tsang, T.K., Wu, P., Feng, L., Jiang, H., Peng, Z., Zheng, J., Liao, Q., Li, S., Horby, P.W., Farrar, J.J., Gao, G.F., Tatem, A.J., Yu, H., Global epidemiology of avian influenza A H5N1 virus infection in humans, 1997-2015: a systematic review of individual case data. Lancet Infect. Dis. 16 (2016), e108–e118.
27. Leang, S.K., Kwok, S., Sullivan, S.G., Maurer-Stroh, S., Kelso, A., Barr, I.G., Hurt, A.C., Peramivir and laninamivir susceptibility of circulating influenza A and B viruses. Influenza Other Respir. Viruses 8 (2014), 135–139.
28. Le, Q.M., Kiso, M., Someya, K., Sakai, Y.T., Nguyen, T.H., Nguyen, K.H., Pham, N.D., Ngyen, H.H., Yamada, S., Muramoto, Y., Horimoto, T., Takada, A., Goto, H., Suzuki, T., Suzuki, Y., Kawaoka, Y., Avian flu: isolation of drug-resistant H5N1 virus. Nature, 437, 2005, 1108.
29. Li, X., Zhang, Z., Yu, A., Ho, S.Y., Carr, M.J., Zheng, W., Zhang, Y., Zhu, C., Lei, F., Shi, W., Global and local persistence of influenza A(H5N1) virus. Emerg. Infect. Dis. 20 (2014), 1287–1295.
30. McKimm-Breschkin, J.L., Rootes, C., Mohr, P.G., Barrett, S., Streltsov, V.A., In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir. J. Antimicrob. Chemother. 67 (2012), 1874–1883.
31. Mok, C.K., Lee, H.H., Chan, M.C., Sia, S.F., Lestra, M., Nicholls, J.M., Zhu, H., Guan, Y., Peiris, J.M., Pathogenicity of the novel A/H7N9 influenza virus in mice. MBio, 4, 2013 e00362–13.
32. Okomo-Adhiambo, M., Sleeman, K., Lysén, C., Nguyen, H.T., Xu, X., Li, Y., Klimov, A.I., Gubareva, L.V., Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season. Influenza Other Respir. Viruses 7 (2013), 645–658.
33. Sakoda, Y., Sugar, S., Batchluun, D., Erdene-Ochir, T.O., Okamatsu, M., Isoda, N., Soda, K., Takakuwa, H., Tsuda, Y., Yamamoto, N., Kishida, N., Matsuno, K., Nakayama, E., Kajihara, M., Yokoyama, A., Takada, A., Sodnomdarjaa, R., Kida, H., Characterization of H5N1 highly pathogenic avian influenza virus strains isolated from migratory waterfowl in Mongolia on the way back from the southern Asia to their northern territory. Virology 406 (2010), 88–94.
34. Salomon, R., Hoffmann, E., Webster, R.G., Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection. Proc. Natl. Acad. Sci. U.S.A. 104 (2007), 12479–12481.
35. Shetty, A.K., Peek, L.A., Peramivir for the treatment of influenza. Expert Rev. Anti-Infect. Ther. 10 (2007), 123–143.
36. Subbarao, K., Klimov, A., Katz, J., Regnery, H., Lim, W., Hall, H., Perdue, M., Swayne, D., Bender, C., Huang, J., Hemphill, M., Rowe, T., Shaw, M., Xu, X., Fukuda, K., Cox, N., Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279 (1998), 393–396.
37. Sugaya, N., Kohno, S., Ishibashi, T., Wajima, T., Takahashi, T., Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. Antimicrob. Agents Chemother. 56 (2012), 369–377.
38. World Health Organization (WHO), Influenza at the Human-animal Interface. 2015 Summary and assessment as of 6 January http://www.who.int/influenza/human_animal_interface/Influenza_Summary_IRA_HA_interface_6January2015.pdf (Accessed 11 June 2015).
39. World Health Organization (WHO), Influenza at the Human-animal Interface. 2015 Summary and assessment as of 23 June http://www.who.int/influenza/human_animal_interface/Influenza_Summary_IRA_HA_interface_23_June_2015.pdf (Accessed 11 June 2015).
40. Yen, H.L., Ilyushina, N.A., Salomon, R., Hoffmann, E., Webster, R.G., Govorkova, E.A., Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J. Virol. 81 (2007), 12418–12426.
41. Yun, N.E., Linde, N.S., Zacks, M.A., Barr, I.G., Hurt, A.C., Smith, J.N., Dziuba, N., Holbrook, M.R., Zhang, L., Kilpatrick, J.M., Arnold, C.S., Paessler, S., Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1). Virology 374 (2008), 198–209.